Research programme: herpesvirus inhibitors - Pfizer

Drug Profile

Research programme: herpesvirus inhibitors - Pfizer

Alternative Names: Herpesvirus DNA polymerase inhibitors - Pharmacia; PHA-529311; PHA-568561; PNU 253998; Research programme: herpesvirus inhibitors - Pharmacia

Latest Information Update: 04 Aug 2009

Price : $50

At a glance

  • Originator Pfizer
  • Class Quinolines
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cytomegalovirus infections; Epstein-Barr virus infections; Herpes simplex virus infections; Herpesvirus infections; Varicella zoster virus infections

Most Recent Events

  • 04 Aug 2009 No development reported - Preclinical for Varicella zoster virus infections in USA (unspecified route)
  • 04 Aug 2009 No development reported - Preclinical for Herpesvirus infections in USA (unspecified route)
  • 04 Aug 2009 No development reported - Preclinical for Herpes simplex virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top